Search 

Almac Discovery is a research driven drug discovery company operating within the Almac Group of companies dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS). Our business model is primarily to discover and develop novel First-in-Class drug candidates through to pre-clinical development, and then to seek pharmaceutical or biotech partners for clinical development and commercialisation. Key research themes are two-fold: a) Controlling protein homeostasis through targeting Deubiquitinase (DUB) enzymes, and, b) Generating novel protein drug conjugates (PDCs) utilising single chain antigen recognition domains linked to Almac’s proprietary linker:payload technology.

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

BioPartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government.

Our breakthrough technology combines synthetic and stem cell biology, offering limitless possibilities. Enabling a new generation of cell therapies, providing the best human cells for research and drug discovery, and allowing the control of advanced synthetic biology circuits for biomanufacturing.

Charnwood Molecular is an integrated drug discovery provider with a 25-year track record of delivery to our clients worldwide, many of whom are emerging pharmaceutical companies.

We believe in bringing together the right experts, technologies, capabilities, and passion, to support customer drug discovery projects and deliver potent, selective, and drug-like candidates.  Our experienced project scientists (medicinal chemistry, biology, computational chemistry, ADME/PK and process chemistry) understand the drug discovery process, the importance of physicochemical properties, the interrogation of biological data and generation of SAR, with expertise in all major disease areas and targets.

Since our inception in 1998 we have successfully supported hundreds of life science groups globally, from academic groups and virtual start-ups to established biotechnology and pharmaceutical companies. We place great emphasis on open collaboration in our client relationships. What makes Charnwood Molecular unique is our unwavering passion for the truly ground-breaking science we facilitate and the trusting relationships we build.

We are a leading provider of outsourced commercial, medical and recruitment services to pharmaceutical, biotech and healthcare companies. Working exclusively in the United Kingdom, we have brand strategy, implementation, and recruitment experience from numerous launches across prescription medicines, medical devices, and medical software. We provide a UK launch solution for pharmaceutical, biotech and medtech companies, that is an alternative to out-licensing and traditional distribution arrangements.

Curileum is a biotechnology company in London that focuses on
discovering and developing novel therapeutics to intervene early
in the development of severe GI diseases. With a dynamic team of
scientists committed to translating our science to game-changing
therapies, we have discovered and delivered two first-in-class
preclinical therapeutic candidates and a compelling novel drug
target.
ULI-015 a small molecule to reduce polyp formation and progression
to bowel cancer.
ATZ stem cell therapy to repair an incurable condition in Crohn’s
disease patients.
CSR-1 a soluble regulator in Crohn’s patients that drives chronic gut
inflammation.
Curileum is seeking co-development and licensing partners for its
two de-risked, first-in-class preclinical therapeutic candidates and a
collaboration partner to develop a small molecule antagonist to our
novel drug target driving chronic gut inflammation.
Learn more at curileum.com